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Abstract
  Objective. The aim of this report is to describe the potential clinical utility of tracer  [F-18]-Fluorodeoxyglucose (FDG) uptake, quantitated 
as a standardized uptake value (SUV) by positron emission tomography (PET), to evaluate treatment response to neoadjuvant chemotherapy 
(NAC) in advanced uterine cervical cancer. 
  Methods. We briefly describe the clinical courses of three women with advanced cervical cancer who were treated with neoadjuvant 
chemotherapy (NAC) prior to radical hysterectomy and who were analyzed for correlation with the decrease in tumor volume by magnetic 
resonance imaging  (MR1), in SUV by FDG-PET, and by histologic response. 
 Results. In these individuals, tumor volume and SUV  were decreased by  NAC.  The decrease in SUV by FDG-PET was better correlated 
to histologic response for NAC than  MRI was in advanced cervical cancer. 
  Conclusions. Measurement of SUV by FDG-PET has clinical utility in evaluating treatment response for NAC in advanced cervical 
cancer. Although work in this field is still in the early stages, this report demonstrates that SUV by FDG-PET has the potential to become the 
new standard for monitoring the treatment response of  NAC in  cervical  cancer. This monitoring approach must be proven in a larger number 
of patients for both primary and secondary lesions and should  be further explored in another gynecologic ancer. 
 cc-) 2004 Elsevier Inc. All rights reserved. 
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Introduction
  For many years, the standard approach to determining 
whether a tumor is sensitive or resistant o treatment has 
relied on various anatomic imaging techniques, such as 
computed tomography (CT) and magnetic resonance imag-
ing (MRI) [1]. These techniques have a number  of 
limitations, however, because they  evaluate only the size
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of a lesion, not its viability, proliferative rate, or physiologic 
state. 
  Positron emission tomography (PET) with tracer  [F-18]- 
Fluorodeoxyglucose  (FDG)  (FDG-PET) is a  unique, non-
invasive method for studying biochemical and metabolic 
changes in cancer  tissue [2]. Although work in this  field is 
still in the early stages, studies are already demonstrating 
that it is becoming the new standard for some tumors and 
treatments. However, few  studies monitoring the response 
treatment of  gynecologic ancer have been done with  FDG 
tracers  [3-5], and there has been no comparison of the 
response  determined by  MRI, FDG-PET, and histopatho-
logical studies before and after chemotherapy.
  We briefly describe the clinical courses of three women 
with advanced cervical cancer who were treated with 
 neoadjuvant chemotherapy (NAC) prior to radical hyster-
ectomy. The decrease in tumor volume was compared by 
magnetic resonance imaging (MRI), in standardized uptake 
value (SUV) by FDG-PET, and by histologic response to 
chemotherapy.
Materials and methods 
  A prospective analysis was conducted on patients with 
advanced cervical cancer evaluated at our institution from 
2002 to 2003. The three patients with primary, previously 
untreated, histologically confirmed invasive squamous cell 
carcinoma included were  51, 59, and 72 years old. After the 
diagnosis of cervical cancer, all of them were treated with 
neoadjuvant chemotherapy (NAC) prior to radical hyster-
ectomy. For each patient, comparisons were made of the 
assessment of response determined by  MRI, FDG-PET 
studies, and histopathological  studies  before and after NAC. 
Chemotherapy rotocol 
  Neoadjuvant chemotherapy was done according to the 
following schedule: 25  mg/m2 per day CDDP in 1000 ml of 
physiological saline and 1000  mg/m` per day 5-FU in 
1000 ml of  glucosaline solution were administered contin-
uously through continuous perfusion for 4 days according to 
our published Phase I study [6]. All patients received 
hydration before and after the procedure. Diuretics and 
antiemetics were administrated as necessary. Two treatment 
cycles every 4 weeks were performed, based on  the results 
of our published Phase I study [6]. 
Magnetic resonance imaging 
 MRI was performed using a  1.5-T system (Signa; GE 
Medical Systems). The pelvic imaging protocol utilized 
included axial and sagittal  Tl-weighted gradient-echo 
sequences (TRITE,  89.3/4.1) with the administration of 
an  1V contrast medium. Intravenous gadolinium  diethyle-
netriamine pentaacetic acid (Magnevist; Schering, Tokyo, 
Japan) was administered at the usual dose of  0.1 mmol/kg 
of body weight. In addition, axial and sagittal  T2-
weighted turbo-spin-echo sequences (2800/138) were 
performed [7]. 
PET procedures 
  The three patients underwent PET scanning with a 
whole-body tomography scanner (Advance; General Elec-
tric Medical System, Milwaukee, WI) with continuous 
bladder irrigation. FDG was produced using a small 
cyclotron (OSCAR3; Oxford Instruments, Oxford, UK) 
and an automated synthesis ystem (NKK, Tokyo, Japan).
The patients fasted for at least  12 h before tracer 
administration, and approximately 185 MBq of FDG was 
injected intravenously. Whole-body emission scanning was 
started 40  min after FDG administration, and PET data were 
acquired for 12-14  min with 6-7 bed positions [7-10]. PET 
findings for the transaxial, coronal, and  sagittal sections 
were  interpreted by two experienced nuclear medicine 
physicians  (H.O. and T.K.). 
Image analysis 
  The PET data were reconstructed using the iterative 
reconstruction algorithm and segmented attenuation cor-
rection  (IR/SAC) method, and were resliced into transaxial, 
coronal, and sagittal sections with the grey scale in the 
standardized uptake value (SUV) calculated by the normal-
ization of the regional radioactivity concentration to 
injected dose and body weight. If regions of FDG 
accumulation were manifested on the FDG-PET images, 
the site of each region was  evaluated. The estimation of 
lesions on the  FDG-PET images was based on visual 
correlation with MRI, slice by slice. When tissue samples 
were obtained at laparotomy, the lesions were evaluated 
according to MRI findings  [10]. Hypermetabolic lesions 
that were more intense than physiologic  liver uptake were 
considered positive for malignancy. In the liver, lesions 
cannot be attributed to structures that physiologically 
accumulate  FDG, such as the bladder, the ureters, or the 
gastrointestinal tract [9,10]. 
  For quantitative evaluation of regional radioactivity 
using static FDG-PET images, circular regions of interest 
 (ROIs) 3 mm in diameter were placed manually over the 
hypermetabolic esions in the primary and metastatic lesions 
by one nuclear medicine physician  (H.O.). SUVs were 
obtained from three areas of high radioactivity accumulation 
as visualized in the primary and metastatic lesions, and the 
mean SUV was calculated for each tumor. For statistical 
analysis, mean SUVs were used [10]. 
Pre- and post-treatment  tumor measurements 
  The response to neoadjuvant chemotherapy was analyzed 
on abdominal  MRI using the published Response  Evalua-
tion Criteria in Solid Tumors (RECIST) criteria [11]. 
Surgery was then performed in patients showing a tumor 
response. 
 Histopathological grading 
  Finally, after  surgery, the results of the two methods 
(MRI and FDG-PET) were compared with the histological 
evaluation of the  effects of neoadjuvant chemotherapy 
using the surgical specimens according to the method of 
Shimosato et al.  [12] (Table 1).  In FDG-PET, the 
pretreatment SUV and  posttreatment SUV were compared 
with the histologic evaluation of residual  tumor cells. In
Table 1 
Criteria  for histologic evaluation of effects 
therapy according to Shimamoto  ct al.
of radiotherapy and  chemo-
0 
2a
 2b
3
4
No recognized changed in  tumors, 
Minimal cellular changes presents,  but a majority of tumor cells 
appear  viable. 
Despite the presence of cellular changes and partial 
destruction of the tumor, the tumor is still readily 
recognizable, and a good number of tumor cells appear  viable. 
The tumor destruction is extensive,  but viable cell nests arc present 
in small areas of the tumor (<one-quarter of  the tumor mass, 
excluding areas of coagulation necrosis). 
Only a few scattered, markedly altered, presumable non viable 
tumor cells arc present singly or in small clusters; viable cells are 
hardly encountered. 
No tumor cells remain in any section.
addition, to evaluate treatment effect, the size of the tumor 
was determined by measuring the maximum area in a 
single transaxial section of the contrast-enhanced MRI 
 [11,13].
Results
  Patient 1 is a 51-year-old woman who was diagnosed 
with stage  Ilb advanced cervical cancer according to  the 
criteria of the International Federation of Gynecology and 
Obstetrics [6]. Pelvic MRI confirmed the presence of a 
4.0  x 4.0 cm (maximum diameter in the cross-sectional 
area) cervical mass, which had typical  features of cervical 
cancer as it presented with a high-signal-intensity mass on 
a  T2-weighted MR image. This lesion was shown to be 
highly metabolically active by FDG-PET (SUV  = 6.1). 
MRI and FDG-PET did not reveal other sites of suspected 
metastatic lesions. After the patient received  two-cycle 
 neo-adjuvant chemotherapy, the cervical lesionobviously 
decreased in size (0.5  x 0.5) as shown on  MRI and in 
SUV (0.9) on FDG-PET. After  nco-adjuvant chemo-
therapy, the patient underwent radical hysterectomy. 
Histological examination of the surgical specimen in the 
cervical esion showed some viable tissues surrounding a
necrotic region, thus suggesting a complete response to 
treatment of the cervical lesion, as shown by  MR1 and 
FDG-PET study. 
  Patient 2 is a 59-year-old woman who was diagnosed 
with stage  Mb advanced cervical cancer according to the 
 criteria of FIGO. Pelvic  MRI confirmed the presenceof a 
5.5  x 4.5 cm cervical mass, a 3.0 x 1.5 cm left external 
iliac enlarged lymph node (LN), and a 1.0 x 1.0 cm left 
common iliac enlarged LN. The primary cervical lesion 
was shown to be highly metabolically active by FDG-PET 
(SUV = 9.0). Similarly, the presence of increased  uptake 
both in the left external iliac LN (SUV  = 4.7) and in the 
left common iliac LN (SUV = 2.7) was identified with 
FDG-PET.  After two cycles of neo-adjuvant chemotherapy, 
MRI and FDG-PET studies were repeated. MRI showed a 
significant volume reduction in the cervical esion and the
left common iliac LN (diameters reduced from 5.5 x 4.5 
to 0.9  x 0.9 and from 1.0 x 1.0 to less than 0.5 cm, 
respectively) but did not show a significant volume 
reduction in the left external iliac LN (diameter educed 
from 3.0 x 1.5 to 2.5  x 1.2 cm) (Figs. IA and B). 
However, the FDG-PET study showed a significant 
metabolic activity reduction in all lesions (metabolic 
activity reduced from 9.0 to  2.1 in the primary lesion, 
from 4.7 to 2.3 in the left external iliac LN, and from 2.7 
to undetectable in the left common iliac LN) (Figs.  1C and 
D). Histological examination of the surgical specimen 
showed only a few viable cancer cells in the primary 
lesion and no viable cancer cells in the common iliac LN. 
In the left external iliac LN, which had a disparity in 
volume reduction on MRI and in metabolic activity 
reduction on FDG-PET, few viable cancer cells surround-
ing a necrotic region  were seen. Criteria for histological 
evaluation of effects of chemotherapy according to 
Shimosato et al.  [12] were grade 2b in the left external 
iliac LN (Fig.  1E). Thus, in this case, measurement of
SUV in FDG-PET had a better correlation to histologic 
response for NAC than  MRI did in advanced cervical 
cancer. 
  Patient 3 is a 72-year-old woman who was diagnosed 
with stage  11lb advanced cervical cancer according to 
FIGO. Pelvic  MRI confirmed  the presence of a 4.5  x 
4.0  cm (maximum diameter in MRI) cervical mass. This 
lesion was shown to be highly metabolically active by 
FDG-PET (SUV = 10.1).  MR1 and FDG-PET did not 
reveal other sites of suspected metastatic lesions. After the 
patient received two-cycle neoadjuvant chemotherapy, the 
cervical lesion showed a 100% reduction in size on MR1 
(Figs. 2A and B). However, the FDG-PET study was still 
positive for a primary cervical (SUV  = 6.7) lesion (Figs. 
2C and D). Response to  neoadjuvant chemotherapy was 
evaluated by abdominal  MRI using the RECIST criteria 
 [11]. A complete response was observed in patient3. After 
neo-adjuvant chemotherapy, the patient underwent radical 
hysterectomy. Histological examination of the surgical 
specimen showed many viable cancer cells in the primary 
lesion. Criteria for histological evaluation of effects of 
chemotherapy according to Shimosato  etal. [12] was grade 
2a in the primary  (Fig. 2E). Thus, in this case, measure-
ment of SUV in FDG-PET had a better correlation to 
histologic response for NAC than  MRI did in advanced 
cervical cancer. 
  All three primary, histologically confirmed invasive 
squamous cell carcinoma lesions were shown to be highly 
metabolically active by FDG-PET (SUV  = 6.1, 9.0, and 
10.1, respectively). All patients were evaluable using 
 RECIST criteria [11]. Patient 1 (SUV  =  6.1) and patient 2 
 (SUV = 9.0) were partial responders, and patient 3 (SUV -- 
10.1) was a complete responder. In the three patients, the 
primary uptake of FDG (evaluated using SUV) did not 
correlate with response (evaluated using RECIST) to treat-
ment. And all three patients have had progression-free
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Fig. 1. Case 2: Stage  Mb advanced cervical cancer with left external iliac enlarged lymph node  (LN)(L-arrow) and a left common iliac enlarged LN (L, arrow 
head). Pelvic MRI that was taken before (A) and after (B) treatment with  neoadjuvant chemotherapy showed a significant volume  reduction in the  le-ft common 
iliac LN (L, arrow head) (diameters reduced from  l.0  x 1.0 to less than 0.5 cm) but did not show a significant volume reduction in the left external iliac LN (L, 
arrow) (diameter educed from 3.0  x 1.5 to 2.5 x 1.2 cm). In FDG-PET images,  SUV calculated before (C) and  alter (D) treatment showed a significant 
metabolic activity reduction in all lesions (arrows) (metabolic activity reduced from  4.7 to 2.3 in the left external iliac LN (L, arrow), and from 2.7 to 
undetectable (L, arrow head) in the  common  iliac LN).  (E) In the right external iliac  LN, which had a disparity in volume reduction on  MRI and in metabolic 
activity reduction on  FDG-PET, few viable cancer cells surrounding a necrotic region were seen. Criteria for  histological evaluation  of  effects of chemotherapy 
according to  Shimosato  ct al. was grade 2b in the right external iliac LN (arrow) (original magnification,  40x,  hcmatoxylin  staining).
survival (22, 18, and 12 months for 
 respectively).
Discussion
cases 1, 2, and 3,
  This study clearly indicates the superiority of FDG-PET 
to MRI in monitoring response to chemotherapy treatment. 
Thus, FDG-PET is an important tool for knowing whether 
treatment should continue and when to discontinue  chemo-
therapy for cervical cancer. 
  Clinical imagingof many types, including X-ray, nuclear, 
and ultrasound techniques, is widely used to detect and 
stage cancer. After that is accomplished, the appropriate 
therapy must be chosen, and this may include a combination 
of surgery, radiation, chemotherapy, and biologic therapies 
 [1]. Evaluating the success of such treatment often requires
additional imaging studies. Although cross-sectional images 
obtained with CT and MRI have become standard in 
evaluating treatment response, they create a number of 
issues. The major issues that affect the sensitivity and 
specificity  of detecting response by  measuring size include 
delays in shrinkage of dying tumors, slow growth of tumors 
despite unsuccessful treatment, and the persistence of 
fibrotic or necrotic tumors. 
  Over the past several years, studies of lymphoma  [14,15], 
brain tumor [15], colorectal cancer  [15], and lung cancer 
 [16] have clearly indicated the superiority of FDG-PET to 
cross-sectional  images, such as CT, in monitoring response 
to treatment. However, few studies of gynecologic ancer 
 [3-5] in monitoring response treatment have been done with 
FDG tracers. One of the major reasons for this is that  FDG 
has been somewhat limited in its use in  gynecologic disease 
due to the difficulty in detecting tumors adjacent to the
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Fig. 2. Case 3:  Stage  Mb advanced cervical cancer. Pelvic MRI that was  taken before (A) and after (B) treatment with  ncoadjuvant chemotherapy showed a 
significant volume reduction in cervical lesion  (arrows) (diameters reduced from 4.5 x 4.0 to undetectable). In the FDG-PET images, SUV calculated before 
(C) and after (D) treatment did not show metabolic activity reduction in cervical lesion (arrows) (metabolic activity reduced from  10.1 to 6.7). (E) In the 
primary lesion, which had a disparity in volume reduction on  MRI and in metabolic activity reduction on  FDG-PET, many viable cancer cells were  seen. 
Criteria for histological evaluation of effects of chemotherapy according to Shimosato  ct  al. were grade 2a in the  primary  (arrow) (original  magnification, left: 
4  x, right: 100  x,  hematoxylin staining).
bladder and bowel. To overcome this limitation, in this 
study, FDG-PET with continuous bladder irrigation and at 
least  12-h fasting for patients before tracer administration 
was  used  for evaluating cervical cancer [7-10]. 
  In three patients with advanced cervical cancer presented 
in this report,  we have demonstrated the superiority of FDG-
PET to MRI in monitoring the response of NAC in 
advanced cervical cancer in a histological study. A principal 
 finding of this work is that SUV of  FDG-PET is strongly 
correlated with pathological findings obtained from surgical 
specimens in both the primary and lymph node status. As 
shown here, anatomic imaging  techniques evaluate only the 
size of a lesion, not its viability, proliferative rate, or 
physiologic state. Thus, actually determining whether this 
treatment is  successful and whether it should continue 
should be dependent on  the evaluation of both anatomical 
imaging and  FDG-PET. Knowing when to discontinue 
therapy should also be dependent on both techniques 
because treatments are toxic and very costly.
 It is also important to note that the timing of response is 
certainly the most common issue in  the assessment of 
response chemotherapy. The standard approach for patients 
receiving cytotoxic drugs is to have CT or MRI done every 
2 months  [17]. Even when treatment is successful, it can 
take months to become evident in  CT or MRI, and it is 
 difficult to differentiate cases with slowly growing tumors in 
which treatment is not helping from those in which the 
treatment has induced a decrease in the tumor growth rate. 
In this study, we used PET at the end of a course of 
treatment, 2 months after the  first treatment. For this report, 
it was  considered appropriate that the timing of the response 
was at the end of treatment. When  evaluating response to 
therapy, we quantitated the imaging results with a semi-
quantitative valuation using SUV. If the SUV was still 
high, another treatment was considered because failed 
primary treatment iscritical and carries the worst prognosis. 
In this report, it was considered that malignant lesions had a 
value of more than 2.0 [9].
  Based on this experience, in primary cervical cancer, 
measurement of treatment by FDG-PET may become more 
important as more successful treatment options become 
available. It is important for this imaging approach to be 
evaluated in another gynecologic cancer.
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